Cumberland jumps as heart drug for muscle‑wasting disease gets FDA's fast-track tag

Shares of  drugmaker Cumberland Pharmaceuticals CPIX.O rise 15.04% to $4.36

 Co says FDA granted fast track status to its experimental drug ifetroban for heart disease tied to Duchenne muscular dystrophy, a muscle‑wasting condition that weakens the heart

 Co says ifetroban is an oral treatment and has orphan drug and rare pediatric disease tags

A recent mid-stage study showed a 5.4% improvement in heart function after 12 months of treatment, co says

U.S. FDA's "fast track" tag aims to speed development and review of drugs for serious conditions with unmet medical needs

Duchenne muscular dystrophy affects boys and gradually damages muscles, including the heart, leading to life‑threatening complications

Shares up ~68% in 2025